Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 14;11(24):7423.
doi: 10.3390/jcm11247423.

Oral Anticoagulant Use and Appropriateness in Elderly Patients with Atrial Fibrillation in Complex Clinical Conditions: ACONVENIENCE Study

Clara Bonanad  1   2   3 , Francesc Formiga  4 , Manuel Anguita  5 , Roberto Petidier  6 , Alejandra Gullón  7
Affiliations

Oral Anticoagulant Use and Appropriateness in Elderly Patients with Atrial Fibrillation in Complex Clinical Conditions: ACONVENIENCE Study

Clara Bonanad et al. J Clin Med. .

Abstract

Non-valvular atrial fibrillation (NVAF) is the most common arrhythmia in older patients. Although direct-acting oral anticoagulants (DOAC) are the antithrombotic treatment of choice, irrespective of age, certain factors may limit their use. The aim of the ACONVENIENCE study was to consult the opinion of a multidisciplinary panel of experts on the appropriateness of using OACs in elderly patients (>75 years) with NVAF associated with certain complex clinical conditions. A consensus project was performed on the basis of a systematic review of the literature, and application of a two-round Delphi survey. The agreement of 79 panellists on 30 Delphi-type statements was evaluated, and their opinion on the appropriateness of different oral anticoagulants in 16 complex clinical scenarios was assessed. A total of 27 consensus statements were agreed upon, including all statements addressing anticoagulation in older patients and in patients at high risk of bleeding complications, and most of those addressing frailty, dementia, risk of falling, and complex cardiac situations. It was almost unanimously agreed upon that advanced age should not influence the anticoagulation decision. Apixaban was the highest-rated therapeutic option in 14/16 situations, followed by edoxaban. There is a high degree of agreement on anticoagulation in older patients with NVAF. Age should not be the single limiting factor when prescribing OACs, and the decision should be made based on net clinical benefit and a comprehensive geriatric assessment. Apixaban, followed by edoxaban, was considered the most appropriate treatment in the various complex clinical situations examined.

Keywords: anticoagulants; antithrombins; atrial fibrillation; bleeding; drug interactions; factor Xa inhibitors; frail elderly; geriatric assessment; stroke.

PubMed Disclaimer

Conflict of interest statement

C. Bonanad declares that she has received funding for attendance at meetings and conferences, and speaker fees from BMS/Pfizer, Daiichi-Sankyo, Boehringer and Bayer. F. Formiga received funding for attendance at meetings and congresses, honoraria and funding from Pfizer for attending meetings and congresses; speaker fees from BMS/Pfizer, Daiichi-Sankyo, and Bayer; and funding for participating in research by BMS/Pfizer. M. Anguita declares that he has received speaker fees from BMS/Pfizer, Novartis, Bayer, Daiichi-Sankyo and Boehringer, and funding for participating in research projects from BMS/Pfizer, Abbot, Novartis, Bayer, and Daiichi-Sankyo. R. Petidier declares that he has received speaker fees from Bayer, BMS/Pfizer and Daiichy-Sankyo. A. Gullón declares that she has received speaker fees from BMS/Pfizer and Bayer and funding for participating in a research project from Daiichi-Sankyo.

Figures

Figure 1
Figure 1
PRISMA 2020 flow diagram of the databases and registry search performed for the systematic literature review.
Figure 2
Figure 2
Mean score for available anticoagulation options in different clinical situations that may be encountered in elderly patients (maximum score = 10; minimum score = 1). ACS, acute coronary syndrome; AMI, acute myocardial infarction; API, apixaban; CCS, chronic coronary syndrome; CKD, chronic kidney disease; DAB, dabigatran; EDO, edoxaban; GFR, glomerular filtration rate; GIB, gastrointestinal bleeding; NVAF, non-valvular atrial fibrillation; RIV, rivaroxaban; TAVI, transcatheter aortic valve implantation; VKA, vitamin K antagonists. * The question was made on the OAC with less risk of drug interactions.
See this image and copyright information in PMC

References

    1. Gómez-Doblas J.J., Muñiz J., Martin J.J.A., Rodríguez-Roca G., Lobos J.M., Awamleh P., Permanyer-Miralda G., Chorro F.J., Anguita M., Roig E. Prevalence of Atrial Fibrillation in Spain. OFRECE Study Results. Rev. Esp. Cardiol. Engl. Ed. 2014;67:259–269. doi: 10.1016/j.recesp.2013.07.015. - DOI - PubMed
    1. Pérez-Villacastín J., Castellano N.P., Planas J.M. Epidemiología de la fibrilación auricular en España en los últimos 20 años. Rev. Esp. Cardiol. 2013;66:561–565. doi: 10.1016/j.recesp.2013.02.013. - DOI - PubMed
    1. Benjamin E.J., Levy D., Vaziri S.M., D’Agostino R.B., Belanger A.J., Wolf P.A. Independent Risk Factors for Atrial Fibrillation in a Population-Based Cohort: The Framingham Heart Study. JAMA. 1994;271:840–844. doi: 10.1001/jama.1994.03510350050036. - DOI - PubMed
    1. Marinigh R., Lip G.Y., Fiotti N., Giansante C., Lane D.A. Age as a Risk Factor for Stroke in Atrial Fibrillation Patients: Implications for Thromboprophylaxis. J. Am. Coll. Cardiol. 2010;56:827–837. doi: 10.1016/j.jacc.2010.05.028. - DOI - PubMed
    1. Pisters R., Lane D.A., Nieuwlaat R., de Vos C.B., Crijns H.J., Lip G.Y. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. Chest. 2010;138:1093–1100. doi: 10.1378/chest.10-0134. - DOI - PubMed

LinkOut - more resources